nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.02.2006 | Original Article

¹¹C-methionine PET for the diagnosis and management of recurrent pituitary adenomas

verfasst von: B. N. T. Tang, M. Levivier, M. Heureux, D. Wikler, N. Massager, D. Devriendt, P. David, N. Dumarey, B. Corvilain, S. Goldman

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 2/2006

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The detection of recurrent pituitary adenoma by magnetic resonance imaging (MRI) is rendered uncertain by the tissue remodelling that follows surgery or radiotherapy. We aimed to evaluate the contribution of PET with ¹¹C-methionine (MET-PET) in the detection and management of recurrent pituitary adenoma.

Methods

Thirty-three patients with pituitary adenoma were evaluated postoperatively by MET-PET, either because of biological evidence of active residual tumour or because of MRI demonstration of non-functional adenoma growth. We studied 24 secreting adenomas and nine non-functional adenomas.

Results

In 30 patients, MET-PET detected abnormally hypermetabolic tissue. In 14 out of these, MRI did not differentiate between residual tumour and scar formation. In nine of these 14 cases, major therapeutic decisions were undertaken (radiosurgery and surgery). In another group of 16 patients, both MET-PET and MRI detected abnormal tissue. In one case, neither MRI nor MET-PET detected adenomatous tissue. Finally, abnormal tissue was detected in two patients on MRI solely. In these two cases, failure of MET-PET to reveal the adenoma was attributable to concomitant inhibitory therapy. The sensitivity of MET-PET and MRI varied as a function of the tumour type: all non-functional adenomas were localised by both modalities, while MET-PET detected all adrenocorticotropic hormone-secreting adenomas whereas MRI depicted only one of these eight lesions. Fifteen out of 17 patients treated by radiosurgery showed clinical improvement after treatment.

Conclusion

We suggest that MET-PET is a sensitive technique complementary to MRI for the detection of residual or recurrent pituitary adenomas. It should gain a place in the efficient management of these tumours.

Kuratsu J, Takeshima H, Ushio Y. Trends in the incidence of primary intracranial tumors in Kumamoto, Japan. Int J Clin Oncol 2001;6:183–91PubMed

Ferrari G, Lovaste MG, Moresco M, Rossi G. Primary intracranial tumors. Survey of incidence in the province of Trento in the years 1977–1981. Ital J Neurol Sci 1985;6:191–6PubMed

Biermasz NR, van Dulken H, Roelfsema F. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. J Clin Endocrinol Metab 2000;85:4596–602CrossRefPubMed

Swearingen B, Barker FG II, Katznelson L, Biller BM, Grinspoon S, Klibanski A, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3419–26CrossRefPubMed

Losa M, Mortini P, Barzaghi R, Gioia L, Giovanelli M. Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. J Clin Endocrinol Metab 2002;87:3180–6CrossRefPubMed

Mampalam TJ, Tyrrell JB, Wilson CB. Transsphenoidal microsurgery for Cushing disease. A report of 216 cases. Ann Intern Med 1988;109:487–93PubMed

Davis PC, Hoffman JC Jr, Tindall GT, Braun IF. CT-surgical correlation in pituitary adenomas: evaluation in 113 patients. Am J Neuroradiol 1985;6:711–6PubMed

Nakane T, Kuwayama A, Watanabe M, Takahashi T, Kato T, Ichihara K, et al. Long term results of transsphenoidal adenomectomy in patients with Cushing’s disease. Neurosurgery 1987;21:218–22PubMed

Losa M, Giovanelli M, Persani L, Mortini P, Faglia G, Beck-Peccoz P. Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 1996;81:3084–90CrossRefPubMed

10.

Sano T, Yamada S. Histologic and immunohistochemical study of clinically non-functioning pituitary adenomas: special reference to gonadotropin-positive adenomas. Pathol Int 1994;44:697–703PubMed

11.

Sheehan JP, Kondziolka D, Flickinger J, Lunsford LD. Radiosurgery for residual or recurrent nonfunctioning pituitary adenoma. J Neurosurg 2002;97:408–14

12.

Shin M. Gamma knife radiosurgery for pituitary adenoma. Biomed Pharmacother 2002;56 Suppl 1:178s–81sCrossRefPubMed

13.

Kremer P, Forsting M, Hamer J, Sartor K. MR imaging of residual tumor tissue after transsphenoidal surgery of hormone-inactive pituitary macroadenomas: a prospective study. Acta Neurochir Suppl 1996;65:27–30PubMed

14.

Kremer P, Forsting M, Ranaei G, Wuster C, Hamer J, Sartor K, et al. Magnetic resonance imaging after transsphenoidal surgery of clinically non-functional pituitary macroadenomas and its impact on detecting residual adenoma. Acta Neurochir (Wien) 2002;144:433–43CrossRef

15.

Rodriguez O, Mateos B, de la Pedraja R, Villoria R, Hernando JI, Pastor A, et al. Postoperative follow-up of pituitary adenomas after trans-sphenoidal resection: MRI and clinical correlation. Neuroradiology 1996;38:747–54CrossRefPubMed

16.

Steiner E, Knosp E, Herold CJ, Kramer J, Stiglbauer R, Staniszewski K, et al. Pituitary adenomas: findings of postoperative MR imaging. Radiology 1992;185:521–7PubMed

17.

Kaiser WA, Steckelbroeck V, Siewert B, Layer G, Hochstetter A, Reiser M. Differentiating between tumor and implant material in the postoperative sella using MRT. Rofo 1993;158:555–64PubMed

18.

Battistin L, Gerstenbrand F. PET and NMR: new perspectives in neuroimaging and in clinical neurochemistry. New York: Liss; 1986. p. 407–24

19.

Bergstrom M, Muhr C, Lundberg PO, Langstrom B. PET as a tool in the clinical evaluation of pituitary adenomas. J Nucl Med 1991;32:610–5PubMed

20.

Comar D, Cartron J, Maziere M, Marazano C. Labelling and metabolism of methionine-methyl-¹¹C. Eur J Nucl Med 1976;1:11–4CrossRefPubMed

21.

Goldman S, Levivier M, Pirotte B, Brucher JM, Wikler D, Damhaut P, et al. Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy. J Nucl Med 1997;38:1459–62PubMed

22.

Sakamoto Y, Takahashi M, Korogi Y, Bussaka H, Ushio Y. Normal and abnormal pituitary glands: gadopentetate dimeglumine-enhanced MR imaging. Radiology 1991;178:441–5PubMed

23.

Peck WW, Dillon WP, Norman D, Newton TH, Wilson CB. High-resolution MR imaging of pituitary microadenomas at 1.5 T: experience with Cushing disease. Am J Roentgenol 1989;152:145–51

24.

Cano A, Martinez M, Benito P, Tofe S, Higuera A, Munoz R. Analysis of indirect signs of microprolactinoma at MR imaging. Eur J Radiol 1999;31:157–64CrossRefPubMed

25.

Levivier M. Integration of metabolic data by positron emission tomography in image-guided neurosurgical interventions [in French]. Bull Mem Acad R Med Belg 2002;157:235–45; discussion 245–50PubMed

26.

Levivier M, Massager N, Wikler D, Lorenzoni J, Ruiz S, Devriendt D, et al. Use of stereotactic PET images in dosimetry planning of radiosurgery for brain tumors: clinical experience and proposed classification. J Nucl Med 2004;45:1146–54PubMed

27.

Tang BN, Sadeghi N, Branle F, De Witte O, Wikler D, Goldman S, et al. Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma. J Neurooncol 2005;71:161–8CrossRefPubMed

28.

Yoon PH, Kim DI, Jeon P, Lee SI, Lee SK, Kim SH. Pituitary adenomas: early postoperative MR imaging after transsphenoidal resection. Am J Neuroradiol 2001;22:1097–104PubMed

29.

Rajaraman V, Schulder M. Postoperative MRI appearance after transsphenoidal pituitary tumor resection. Surg Neurol 1999;52:592–8; discussion 598–9CrossRefPubMed

30.

Bergstrom M, Muhr C, Lundberg PO, Bergstrom K, Gee AD, Fasth KJ, et al. Rapid decrease in amino acid metabolism in prolactin-secreting pituitary adenomas after bromocriptine treatment: a PET study. J Comput Assist Tomogr 1987;11:815–9PubMed

31.

Muhr C, Bergstrom M. Positron emission tomography applied in the study of pituitary adenomas. J Endocrinol Invest 1991;14:509–28PubMed

32.

Scippo ML, Beckers A, Frankenne F, Reznik M, Stevenaert A, Igout A, et al. Adenohypophysis hormone gene products in 14 pituitary adenomas: analysis by immunohistochemistry and northern blotting. Arch Int Physiol Biochim Biophys 1991;99:135–40PubMed

33.

Jameson JL, Klibanski A, Black PM, Zervas NT, Lindell CM, Hsu DW, et al. Glycoprotein hormone genes are expressed in clinically nonfunctioning pituitary adenomas. J Clin Invest 1987;80:1472–8PubMed

34.

Yeh PJ, Chen JW. Pituitary tumors: surgical and medical management. Surg Oncol 1997;6:67–92CrossRefPubMed

35.

Buchfelder M, Nistor R, Fahlbusch R, Huk WJ. The accuracy of CT and MR evaluation of the sella turcica for detection of adrenocorticotropic hormone-secreting adenomas in Cushing disease. Am J Neuroradiol 1993;14:1183–90PubMed

36.

Levivier M, Goldman S, Bidaut LM, Luxen A, Stanus E, Przedborski S, et al. Positron emission tomography-guided stereotactic brain biopsy. Neurosurgery 1992;31:792–7; discussion 797PubMed

37.

Levivier M, Goldman S, Pirotte B, Brucher JM, Baleriaux D, Luxen A, et al. Diagnostic yield of stereotactic brain biopsy guided by positron emission tomography with [¹⁸F]fluorodeoxyglucose. J Neurosurg 1995;82:445–52PubMed

38.

Levivier M, Wikier D, Goldman S, David P, Metens T, Massager N, et al. Integration of the metabolic data of positron emission tomography in the dosimetry planning of radiosurgery with the gamma knife: early experience with brain tumors. Technical note. J Neurosurg 2000;93 Suppl 3:233–8PubMed

39.

Goldman S, Levivier M, Pirotte B, Brucher JM, Wikler D, Damhaut P, et al. Regional glucose metabolism and histopathology of gliomas. A study based on positron emission tomography-guided stereotactic biopsy. Cancer 1996;78:1098–106CrossRefPubMed

40.

Brada M, Ajithkumar TV, Minniti G. Radiosurgery for pituitary adenomas. Clin Endocrinol (Oxf) 2004;61:531–43CrossRef

41.

De Souza B, Brunetti A, Fulham MJ, Brooks RA, DeMichele D, Cook P, et al. Pituitary microadenomas: a PET study. Radiology 1990;177:39–44PubMed

42.

Hanakawa K, Ikeda H, Ishii K, Asamoto S, Iwata T, Matsumoto K, et al. High uptake on¹¹C methionine PET scan in the pituitary gland of a patient with cerebral glioma after surgical abortion [in Japanese]. No To Shinkei 1998;50:573–7PubMed

43.

Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002;32:148–55CrossRefPubMed

44.

Colao A, Lastoria S, Lombardi G. Receptor imaging in the diagnosis and treatment of pituitary tumors. J Endocrinol Invest 1999;22:736–7PubMed

45.

Boni G, Ferdeghini M, Bellina CR, Matteucci F, Castro Lopez E, Parenti G, et al. [¹¹¹In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas. Q J Nucl Med 1995;39:90–3PubMed

46.

Koga M, Nakao H, Arao M, Sato B, Noma K, Morimoto Y, et al. Demonstration of specific dopamine receptors on human pituitary adenomas. Acta Endocrinol (Copenh) 1987;114:595–602

Titel: 11C-methionine PET for the diagnosis and management of recurrent pituitary adenomas
verfasst von: B. N. T. Tang
M. Levivier
M. Heureux
D. Wikler
N. Massager
D. Devriendt
P. David
N. Dumarey
B. Corvilain
S. Goldman
Publikationsdatum: 01.02.2006
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 2/2006
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-005-1882-0

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

¹¹C-methionine PET for the diagnosis and management of recurrent pituitary adenomas

Abstract

Purpose

Methods

Results

Conclusion

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2006

Assessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancer

Reversibility of ecstasy-induced reduction in serotonin transporter availability in polydrug ecstasy users

PET recognition of pulmonary metastases on PET/CT imaging: impact of attenuation-corrected and non-attenuation-corrected PET images

Effect of diazepam on the efficacy of dual-phase FDG PET imaging

Demonstration of a right inguinal hernia containing urinary bladder diverticulum on whole-body bone scan and pelvic CT

Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson’s disease